American Society of Hirudotherapy

Migraine

Investigational use; the only clinical studies found in journal searches are a 7-patient case series and a 26-patient non-randomized pilot (older reports are described in “What the books describe”), and the proposed mechanism is hypothetical.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 17, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for migraine. The FDA cleared medicinal leeches in 2004 (K040187) only for venous congestion in microsurgical reconstruction. Use for migraine is investigational and not FDA-evaluated.
What evidence exists?
Only two small studies were identified in our journal searches: a case series of 7 patients with chronic migraine (Ansari 2019) and a non-randomized pilot of 26 patients that found no significant difference between leech therapy and preventive drug therapy at 3 months (Bakhshi 2015). A Russian medical book also retells older reports that include people with migraine or migraine-like headaches, but gives no separate result for them (see “What the books describe” below). Tier C (investigational). No randomized controlled trial was identified. Migraine trials show high placebo response, so uncontrolled improvements should be interpreted cautiously. Evidence-based preventive therapies (CGRP inhibitors, topiramate, beta-blockers, onabotulinumtoxinA) remain first-line.
Main risks
  • Bleeding from each bite site for 6 to 24 hours after detachment
  • Bruising and tenderness around the temples, mastoid, and neck for 3 to 7 days
  • Itching and irritation at bite sites for days to weeks
  • Local skin infection or, rarely, Aeromonas infection from leech gut bacteria (~1-20% across hirudotherapy generally)
  • Allergic reaction to leech saliva (uncommon)
  • Temporary worsening of headache for 1 to 2 days after the session
  • Small bite marks that usually fade over weeks to months (rarely a pale spot stays longer)
  • TRIGGER RISK: many migraine patients have specific triggers; placement may precipitate attacks
  • Delay of FDA-approved CGRP monoclonal antibodies, onabotulinumtoxinA, topiramate, propranolol
Who should not consider this
  • Patients taking blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, or heparin
  • Patients with hemophilia or other inherited bleeding disorders
  • Patients with anemia
  • Patients with a weakened immune system
  • Patients with secondary headache (rule out tumor, hemorrhage, infection first via neurology workup)
  • Patients with active medication-overuse headache (analgesic withdrawal needed first)
  • Patients with red-flag headache features (sudden onset, neurological deficits, fever, immunosuppression, age over 50 new-onset)
  • Patients with active dermatitis or broken skin at planned placement sites
  • Pregnant patients (migraine prevention strategy is different in pregnancy)
What to ask your clinician
  • Have I been evaluated by a neurologist and had imaging if indicated to rule out secondary causes?
  • Have I completed an adequate trial of evidence-based preventives (topiramate, beta-blockers, CGRP inhibitors, onabotulinumtoxinA)?
  • What evidence supports leech therapy for my migraine specifically, and what is the realistic chance of benefit?
  • What is the practitioner's experience treating migraine with leech therapy?
  • What antibiotic plan do you use for Aeromonas prevention?
  • What red flags require me to seek urgent care?
  • What is the cost, and is it covered by insurance? (typically not)
  • Am I using acute therapy more than 10 to 15 days per month (medication-overuse headache risk)?
  • What is the practitioner's plan if I have a migraine attack during or after a session?
When to seek urgent care
  • Sudden worst headache of life or thunderclap headache (possible subarachnoid hemorrhage — call 911)
  • Headache with fever, neck stiffness, confusion, or rash (possible meningitis)
  • New neurologic symptoms — weakness, numbness, speech difficulty, vision loss
  • Bleeding from a bite site lasting more than 24 to 48 hours, or soaking through dressings
  • Spreading redness, warmth, pus, or red streaks at bite sites (cellulitis or Aeromonas)
  • Fever above 38.0 C / 100.4 F or chills
  • Hives, throat tightness, or breathing difficulty
  • Jaw claudication, scalp tenderness, or vision change in age over 50 (possible giant cell arteritis)
  • Migraine with aura lasting more than 1 hour, or atypical aura

What this does NOT mean

  • This is not FDA-cleared for migraine.
  • Mechanism rationale (venous decongestion, anti-inflammatory peptides) does NOT establish clinical efficacy.
  • Uncontrolled case series are not evidence of efficacy beyond placebo, especially in a condition with high placebo response.
  • Leech therapy is not a substitute for neurologic evaluation or evidence-based preventive therapy.
  • Reported benefit in small series does not predict individual response.
  • Medication-overuse headache must be addressed first if present.

Clinical Profile

Category
Neurological
ICD-10
G43.009, G43.109, G43.709, G43.719, G43.819
Safety tier
Low

Evidence Summary

No randomized controlled trial of leech therapy for migraine was identified, and PubMed indexes no clinical study of it. Two small studies exist in journals outside PubMed: a case series of 7 patients with chronic migraine who had failed oral treatment (Ansari 2019; fewer headache and migraine days and less analgesic use after 2 months, no control group) and a quasi-experimental pilot of 26 patients that compared leech therapy with preventive drug therapy (propranolol 80 mg/day plus amitriptyline 50 mg/day) and found no significant difference between the groups at 3 months (Bakhshi 2015). The 2004 monograph by Baskova and Isakhanyan lists migraine among indications and retells older Russian observations that include patients with migraine or migraine-like headaches, without a separate result for migraine (see “What the books describe” below). Proposed mechanisms (reduction of cervico-cranial venous congestion and modulation of trigeminovascular inflammation via local salivary peptides) are hypothetical. Given the well-documented high placebo response in migraine trials, any uncontrolled impression of benefit is unreliable. Use is investigational and should be reserved, if considered at all, for chronic migraine refractory to conventional preventive therapy.

What the books describe

Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.

  • Baskova and Isakhanyan name migraine in lists: according to the conclusion by Bottenberg (1983) that they cite, the method is indicated in a number of nervous diseases, among them migraine, and migraine also appears in their list of diseases for which, citing published information, treatment with leeches is recommended[B1].
  • Neither book has a separate section on the treatment of migraine, a treatment scheme, a separately named result for patients with migraine, a division into episodic and chronic migraine, or an account of a course of leeches to prevent attacks[B1][B3].
  • They retell data by Lukashev (1948): of 616 patients with diseases of the nervous system, 23 had migraine, and leeches were prescribed “with a good effect”; the result for migraine is not named separately, and how the effect was assessed is not clear from the text[B1].
  • They also cite an observation by Stroganova (1999) of 95 children with various neurological disorders, of whom 12 had “migraine-like headaches”; the outcomes are given for the whole group and not named separately for these 12 children[B1].
  • Michalsen, in Chapter 10, mentions migraine only as an example of an old theory: one author linked the treatment of migraine to a particular connective tissue zone; he writes that the available data are insufficient to say reliably whether there are clinical indications based on such mechanisms[B3].
  • Among the contraindications, Baskova and Isakhanyan name hemophilia, hemorrhagic diatheses, anemia, low blood pressure, acute vascular insufficiency (shock, collapse, fainting), exhaustion (cachexia), concurrent use of anticoagulants and alcohol, and individual intolerance; they advise refraining when body temperature is high, call the question of pregnancy open, and regard prescribing leeches in large numbers, for long periods, without breaks or with short breaks as unjustified and impermissible[B1].
  • Flecken and Michalsen (Chapter 8) call hemophilia and the use of anticoagulants an absolute contraindication, write that aspirin and clopidogrel are not in themselves a contraindication (in which case fewer leeches are needed at the first session), and that in anemia and in pregnancy treatment involving blood loss is, as a rule, contraindicated; this is only part of the contraindications listed in the books[B3].

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Secondary headache (rule out before treatment)
  • Current ergot or triptan overuse headache
  • Medication-overuse headache without prior taper

Related Conditions

References

  • [B1]

    Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]

    Москва: Монолит(2004)https://search.rsl.ru/ru/record/01007959553

    Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.

  • [B3]

    Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy

    Stuttgart — New York: Thieme(2007)https://books.google.com/books?vid=ISBN9781588905635

    ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.

The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.